[{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"15","companyTruncated":"KVK.Tech \/ Medix"}]

Find Clinical Drug Pipeline Developments & Deals for Phentermine HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

AAN
Not Confirmed
AAN
Not Confirmed

Details : Through the partnership, Medix will gain the exclusive rights to manufacture, distribute, and market Lomaira (Phentermine Hydrochloride) in Mexico. It is indicated for the treatment of obesity.

Product Name : Lomaira

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

July 31, 2024

Lead Product(s) : Phentermine Hydrochloride

Therapeutic Area : Nutrition and Weight Loss

Highest Development Status : Approved FDF

Sponsor : Medix

Deal Size : Undisclosed

Deal Type : Partnership

blank